14.19
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché RDY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$14.12
Aprire:
$14.21
Volume 24 ore:
671.88K
Relative Volume:
0.49
Capitalizzazione di mercato:
$11.85B
Reddito:
$3.85B
Utile/perdita netta:
$667.93M
Rapporto P/E:
21.60
EPS:
0.657
Flusso di cassa netto:
$142.30M
1 W Prestazione:
-0.35%
1M Prestazione:
+1.79%
6M Prestazione:
+11.21%
1 anno Prestazione:
-12.52%
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Confronta RDY con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
RDY
Dr Reddys Laboratories Ltd Adr
|
14.19 | 11.75B | 3.85B | 667.93M | 142.30M | 0.657 |
![]()
ZTS
Zoetis Inc
|
152.43 | 67.75B | 9.39B | 2.62B | 2.22B | 5.81 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.15 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
![]()
HLN
Haleon Plc Adr
|
9.89 | 43.70B | 14.26B | 1.98B | 2.47B | 0.4347 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.76 | 21.51B | 16.70B | -157.13M | 1.19B | -0.155 |
![]()
UTHR
United Therapeutics Corp
|
391.45 | 18.31B | 2.99B | 1.21B | 1.13B | 25.06 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
2024-12-19 | Downgrade | Nomura | Buy → Neutral |
2024-01-11 | Downgrade | Jefferies | Buy → Underperform |
2023-08-29 | Downgrade | HSBC Securities | Buy → Hold |
2023-05-18 | Downgrade | Bernstein | Outperform → Mkt Perform |
2023-03-17 | Aggiornamento | BofA Securities | Neutral → Buy |
2023-01-30 | Iniziato | JP Morgan | Underweight |
2022-11-14 | Downgrade | Credit Suisse | Neutral → Underperform |
2022-01-03 | Ripresa | BofA Securities | Neutral |
2021-07-27 | Downgrade | Credit Suisse | Outperform → Neutral |
2021-02-02 | Aggiornamento | Barclays | Equal Weight → Overweight |
2020-09-18 | Aggiornamento | BofA Securities | Neutral → Buy |
2020-09-18 | Aggiornamento | Investec | Sell → Hold |
2020-01-28 | Downgrade | CLSA | Buy → Outperform |
2020-01-27 | Downgrade | CLSA | Buy → Outperform |
2020-01-09 | Aggiornamento | Citigroup | Sell → Buy |
2019-11-04 | Downgrade | BofA/Merrill | Buy → Neutral |
2019-09-04 | Aggiornamento | Credit Suisse | Underperform → Outperform |
2019-07-01 | Aggiornamento | Macquarie | Neutral → Outperform |
2019-06-20 | Iniziato | Deutsche Bank | Hold |
2019-06-11 | Iniziato | Barclays | Equal Weight |
2019-05-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2019-02-19 | Aggiornamento | CLSA | Outperform → Buy |
2019-01-17 | Downgrade | Citigroup | Neutral → Sell |
2017-09-21 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2017-08-31 | Aggiornamento | CLSA | Underperform → Outperform |
2017-07-28 | Downgrade | CLSA | Underperform → Sell |
2016-07-27 | Downgrade | HSBC Securities | Hold → Reduce |
2016-07-27 | Downgrade | Jefferies | Hold → Underperform |
2016-02-10 | Aggiornamento | Credit Agricole | Underperform → Buy |
2015-11-10 | Downgrade | Citigroup | Buy → Neutral |
Mostra tutto
Dr Reddys Laboratories Ltd Adr Borsa (RDY) Ultime notizie
Mixed Performance For Asian Stocks Traded In The US - Finimize
Validea's Top Health Care Stocks Based On Peter Lynch8/25/2025 - Nasdaq
Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - Barchart.com
Asian ADRs Trade Lower As S&P Asia 50 Index Drops - Finimize
Asian Tech Names Lift US-Traded Stocks To A Small Gain - Finimize
LLY Stock Quote Price and Forecast - CNN
Dr. Reddy’s Subsidiary Imperial Dissolved Following NCLT Approval - TipRanks
Trump Tariff Impact: Infosys, Wipro, HDFC Bank, Other ADR Shares Drop After US Levies 50% Tariff On India - MSN
Asian Stocks In The US See Mixed Moves Across Sectors - Finimize
Trump hikes tariffs on India by additional 25% citing Russian oil trade; iShares India ETF, ADRs react - Moneycontrol
Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT - GlobeNewswire Inc.
Asian ADRs Fall As Winners And Losers Stand Out - Finimize
Dr Reddys Laboratories Faces Continued Stock Decline Amid Broader Market Challenges - Markets Mojo
Asian ADRs Falter On US Markets As Fintechs Slide - Finimize
Trump Tariff Impact: Infosys, Wipro, HDFC Bank, Other ADR Shares Drop After US Levies 25% Tariff On India - MSN
NVO Stock Quote Price and Forecast - CNN
Asian Stocks Listed In The US Kicked Off The Week Lower - Finimize
Asian Stocks Dipped As US-Listed ADRs Edged Lower - Finimize
Stocks To Watch Today: Infosys, TCPL, Coforge, Bajaj Housing, Persistent Systems, Bikaji Foods - NDTV Profit
Stock Picks Today: Infosys, Dr. Reddys Labs, Kajaria Ceramics, Tata Consumer Products On Brokerages Radar - NDTV Profit
Asian Stocks Mixed As S&P Asia 50 ADR Index Falls - Finimize
Dr Reddy's Q1 Results Preview: Analysts Outlook Mixed, See Double-Digit Growth - MSN
Dr. Reddy’s Labs ADR earnings missed, revenue fell short of estimates - Investing.com Australia
India's Dr Reddy's says open to boosting U.S. manufacturing as tariff threat looms - sg.finance.yahoo.com
Stocks to Watch:Stocks to Watch: Infosys, Bajaj Housing Finance, BEML, Persistent Systems and more - CNBC TV18
Dr Reddys Q1 Results Preview: Analysts Outlook Mixed, See Double-Digit Growth - NDTV Profit
Dr. Reddy’s Laboratories Opens Special Window for Share Transfer Requests - TipRanks
HSBC Upgrades Dr. Reddy’s Laboratories Limited (RDY) to Buy from Hold - MSN
Asian ADRs Retreat As Mixed Results Hit The Market - Finimize
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Dr Reddys Laboratories Ltd Adr Azioni (RDY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):